Their conclusion was that low LDL-cholesterol due to PCSK9 or HMGCoA variants were not associated with increased risk for AD, so PCSK9 may be worthy of consideration in the context of T2DM. The gene discussed is PCSK9; the disease is Alzheimer disease.